Wegovy HD vs Wegovy Pill: Which One Is Actually Right for You in 2026

The decision most people are actually making — and why HD is the step-up, not the starting point.

Bottom line up front: If you're searching Wegovy HD vs Wegovy pill, here’s the one thing almost every other page buries: Wegovy HD isn't a starter dose. The FDA label only allows HD (the new 7.2 mg weekly injection) after you've tolerated the standard 2.4 mg Wegovy injection for at least 4 weeks. So if you're new to Wegovy, you're not choosing between HD and the pill — you're choosing between the Wegovy tablet path (starts at 1.5 mg daily, titrates up to 25 mg over about 3 months) and the Wegovy injection path (starts at 0.25 mg weekly, titrates up to 2.4 mg over about 4 months). HD is the step-up option you graduate into later, only if clinically indicated.

If you're already on 2.4 mg and stalled, the real question is HD vs staying put. If you're new and needle-averse, the real question is the tablet path vs the injection path. Two different decisions hiding under one search term — and the rest of this page will tell you which one is yours.

We verified every row against the current Wegovy FDA prescribing information (January 2026 revision), Novo Nordisk's April 2026 NovoCare price guide, and the STEP UP and OASIS 4 trial publications. Provider pages were spot-checked live.

If you already know you want the tablet route, see current Wegovy pill pricing at SHED → (membership required; see access matrix below for full fee breakdown). If you're already on 2.4 mg and stalled, check Wegovy HD eligibility through Hims →. Everyone else — keep reading. The next section tells you in 60 seconds which lane is actually yours.

The One Thing Almost Every Other Wegovy Comparison Page Misses

The quick answer: Wegovy HD is only approved as a step-up from the 2.4 mg injection, not as a starting dose. If you're new to Wegovy, you literally cannot start on HD. That single fact changes most readers' comparison from “HD vs pill” to “tablet path vs injection path.”

The exact language from the current Wegovy prescribing information: adults taking Wegovy for weight reduction “who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated” may increase to “a maximum dosage of 7.2 mg subcutaneously once weekly.”

Translation: HD is the second-gear option. You don't just show up and ask for it on day one.

Most comparison pages online still treat HD as if it's an equal-footing alternative to the pill. It isn't. Pretending otherwise sets readers up to waste a telehealth visit and come back to search more confused. We'd rather tell you the truth in one screen and save you the round trip.

What this means for your decision:

• New to Wegovy? Your real choice is tablet path (1.5 mg → 25 mg) vs injection path (0.25 mg → 2.4 mg). HD comes months later, if at all.
• Already on Wegovy 2.4 mg and plateauing? Your real choice is staying at 2.4 mg, stepping up to HD, or switching to the 25 mg tablet. The tablet won't get you more weight loss than 2.4 mg — they're roughly equivalent. If you need more result, HD is the lane built for that.
• Coming off compounded semaglutide to an FDA-approved home? Start with the tablet path or the standard injection path. HD isn't available to you immediately regardless.

The rest of this page is written for all three of you. Every section will flag which group it matters most for.

Wegovy Starter Paths: Exactly How You Get to the Pill or HD

The quick answer: New patients don't start at the maintenance dose. Wegovy tablets begin at 1.5 mg daily and step up every 30 days until you reach 25 mg (about 3 months total). Wegovy injections begin at 0.25 mg weekly and step up every 4 weeks until you reach 2.4 mg (about 4 months total). HD becomes an option only after at least 4 more weeks of tolerating 2.4 mg. This is almost never explained clearly on one page.

Here's the exact titration schedule from the current FDA prescribing information, side by side:

Wegovy Tablet Starter Path (once daily)

Wegovy Injection Starter Path (once weekly)

So realistically: the tablet path gets you to the 25 mg maintenance dose in about 3 months, and the injection path gets you to 2.4 mg in about 4 months. HD eligibility on the injection path is roughly 5 months in at the earliest — and only if your prescriber agrees more weight loss is needed.

This schedule exists for a reason. GLP-1 side effects get meaningfully rougher when you skip titration steps. Don't improvise, don't stack products, and don't ask a prescriber to fast-track you past tolerability testing.

If You're X, Pick Y — The 60-Second Segmentation

The quick answer: Most readers don't need another 2,000 words of explanation — they need to find themselves in the answer and act. Below is the short version. Every longer section on this page exists to verify one of these choices.

That's the decision. Everything below is the verification.

How Much Weight Do You Actually Lose on Wegovy HD vs the Pill?

The quick answer: In their pivotal trials, adults on Wegovy HD 7.2 mg lost about 18.7% of body weight on average over 72 weeks (up to ~20.7% among those who stayed fully on treatment). Adults on the Wegovy pill 25 mg lost about 13.6% on average over 64 weeks (up to ~16.6% fully adherent). HD has the higher ceiling, but these weren't head-to-head trials — they're separate studies, and the comparison has caveats worth knowing.

What STEP UP showed (Wegovy HD 7.2 mg)

STEP UP was the 72-week phase 3 trial that got Wegovy HD approved. It enrolled 1,407 adults with obesity (BMI ≥30), excluded people with type 2 diabetes, and randomized 5:1:1 to 7.2 mg weekly / 2.4 mg weekly / placebo, all with lifestyle intervention.

Headline numbers for the 7.2 mg arm:

• ~18.7% average weight loss using the treatment-regimen estimand (everyone in the trial, whether they stayed on treatment or not)
• ~20.7% average weight loss using the trial-product estimand (the idealized scenario where everyone stayed on treatment)
• 31.2% achieved ≥25% weight loss — nearly double the rate at 2.4 mg
• 88.7% achieved ≥5% weight loss
• 11.7% discontinued treatment (vs 29.4% on placebo)

Results were published in The Lancet Diabetes & Endocrinology in November 2025.

What OASIS 4 showed (Wegovy pill 25 mg)

OASIS 4 was the 64-week phase 3 trial that got the Wegovy pill approved. It enrolled 307 adults with obesity or overweight plus at least one comorbidity, excluded people with type 2 diabetes, and randomized 2:1 to 25 mg daily oral semaglutide or placebo, with lifestyle intervention.

Headline numbers for the 25 mg pill arm:

• ~13.6% average weight loss treatment-regimen estimand
• ~16.6% average weight loss trial-product estimand
• 76.3% achieved ≥5% weight loss
• ~1 in 3 participants achieved ≥20% weight loss with full adherence
• 18.0% discontinued treatment
• Serious adverse events were lower on oral semaglutide than placebo (3.9% vs 8.8%)

Results were published in The New England Journal of Medicine in 2025.

What the numbers really mean

For a 220-pound adult, the gap between ~14% and ~19% average weight loss is about 11 extra pounds lost over a year and a half. That's real. But here's what we want you to sit with:

These weren't head-to-head trials. STEP UP and OASIS 4 had different populations, different durations, different comparators. You can say HD's official weight-loss ceiling is higher than the pill's ceiling in its trial. You can't say HD “beats” the pill by exactly X pounds for your body.

The pill looks roughly equivalent to the standard 2.4 mg injection on weight loss. That's Novo's own positioning. HD is the first semaglutide form that meaningfully pushes past that plateau.

Your individual result depends on titration, tolerance, and adherence. The 20%+ figure on HD is an idealized scenario. The real-world gap between HD and the pill for your body could be larger, smaller, or — for the right responder on the pill who follows the morning rules perfectly — effectively zero.

Already on 2.4 mg and ready to have the HD conversation with a prescriber? Check HD availability through Hims →

Wegovy HD vs Wegovy Pill: The Real 2026 Cost

The quick answer: As of April 2026, Novo Nordisk's self-pay prices through NovoCare Pharmacy are $399/month for Wegovy HD 7.2 mg, $299/month for the Wegovy pill at 9 mg or 25 mg, and $149/month for the 1.5 mg or 4 mg pill starter doses. A multi-month subscription program launched March 31, 2026 brings the regular Wegovy pen and pill to $249/month on a 12-month plan — but HD wasn't included at launch and is expected to be added later. List price is $1,349.02 per package for all three.

Novo Nordisk self-pay pricing (savings offer, April 2026)

The Novo subscription program (launched March 31, 2026)

Novo Nordisk launched its first multi-month subscription program on March 31, 2026. Launch partners were Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame Care coming online in the weeks after.

Wegovy pen (0.25 mg through 2.4 mg, flat pricing regardless of dose):

• 3-month subscription: $329/month (saves $240/year)
• 6-month subscription: $299/month (saves $600/year)
• 12-month subscription: $249/month (saves $1,200/year)

Wegovy pill (9 mg and 25 mg):

• 3-month subscription: $289/month
• 6-month subscription: $269/month
• 12-month subscription: $249/month (saves up to $600/year)

Wegovy HD 7.2 mg: Not included at launch. Novo's announcement said HD will be added “at a later date.” Until then, HD stays at the $399/month savings-offer price.

That's a real gap worth knowing before you commit. If you go 12-month on the standard pen, you're paying $249/month. If HD becomes necessary later and still isn't in subscription, your monthly cost jumps to $399.

What about insurance?

If you have commercial insurance that covers Wegovy, you may pay as little as $25/month using the Wegovy Savings Offer (max $100/month in savings). Government beneficiaries — Medicare, Medicaid, Tricare — are excluded from the card.

• Many commercial plans exclude Wegovy for weight management; coverage varies widely.
• California's Medi-Cal stopped covering Wegovy for weight management on January 1, 2026.
• Wegovy 1.7 mg / 2.4 mg injection and Wegovy 25 mg tablets are approved to reduce the risk of major cardiovascular events in adults with known heart disease plus obesity or overweight — that's a different indication and can change coverage.
• The Medicare GLP-1 Bridge program was announced to launch July 2026 with a $50/month copay for Wegovy and Zepbound for eligible Part D beneficiaries. Verify enrollment rules at your plan when live.

What's coming in 2027

Novo Nordisk announced in February 2026 that the list price for Wegovy 2.4 mg injection and Wegovy 25 mg tablets will drop to roughly $675/month starting January 1, 2027 — about a 50% cut from the current $1,349 list. That announcement specifically covered those two products; we don't have a confirmed HD-specific list-price change yet. We'll update this page when one is announced.

The biggest objection was price, and now you've seen every real number. Start Wegovy pill at $149/mo via SHED → or See HD options at Hims →

The Part Most Pages Gloss: What Daily Pill Life Actually Looks Like

The quick answer: The Wegovy pill is not the “easy” option if you have chaotic mornings. You have to take it first thing after waking, on an empty stomach, with no more than 4 oz of plain water, and wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication. Miss the timing and absorption drops sharply. The weekly injection has zero timing rules.

The pill demands a structured morning routine. The injection has no timing rules.

We flag this because we see the same disconnect over and over: people assume “pill = easier than shot” and don't find out about the morning fasting window until after they've started.

Why the timing is so strict

Less than 1% of a semaglutide dose reaches the bloodstream through the digestive system even under ideal conditions. The pill uses an absorption enhancer called SNAC (salcaprozate sodium) that temporarily changes the pH of the stomach lining to let more of the drug through. But food, coffee, other pills, or even too much water disrupts that window.

Novo ran OASIS 4 under those strict rules. The 13.6–16.6% weight-loss numbers assume you follow them. Take the pill at inconsistent times or with coffee, and you're not getting the dose your body absorbed in the trial.

The real morning this requires

1. Wake up
2. Take the pill immediately with ≤4 oz plain water
3. Don't eat anything
4. Don't drink coffee, juice, tea, or anything else
5. Don't take other morning medications
6. Wait at least 30 full minutes
7. Then resume a normal morning

What we heard from real patients: “My morning routine is completely disrupted” (Reddit user, r/WegovyWeightLoss). Another user explained the tradeoff directly: “I pass out around needles, so I take the pill… more portable/discreet.” Anecdotal user experiences, not independently verified, not typical results.

For whom the pill actually works better

• People with structured, early mornings
• People who travel often (no refrigeration, small bottle, easy customs)
• People whose real blocker is genuine needle aversion (fainting, phobia — not just preference)
• People who take zero or only evening medications
• People who can reliably wait 30 minutes for coffee

For whom the weekly shot is actually easier

• People with chaotic, variable mornings
• People who take several morning medications already
• People who need coffee immediately upon waking to function
• People who share bathrooms and wake up on different schedules day to day
• People who routinely miss doses when a medication has strict timing rules

The irony: for a huge chunk of readers who assume the pill is easier, the shot is the lower-effort option. You inject once a week, any time of day, with or without food, and forget about it.

If the needle is truly your blocker and you can commit to the morning routine, start Wegovy pill at SHED →. If the morning routine sounds like a nightmare, see the injection path at Sesame →.

Side Effects: The Honest Delta

The quick answer: Both Wegovy formats share the standard GLP-1 side effects — nausea, diarrhea, vomiting, constipation, and abdominal pain. The difference that matters is at the 7.2 mg HD dose: about 22% of patients in the STEP UP trial reported dysesthesia (nerve-related skin sensations like burning, tingling, or a feeling of electrical shock), compared to 6% at 2.4 mg, 5% on the 25 mg pill, and 0.3% on placebo. Most cases resolved on their own or after dose reduction, and the FDA has said it is conducting further investigation.

What each trial reported

The HD dysesthesia signal — our one honest warning

We want to be direct about this. Wegovy HD is not the gentlest-tolerated Wegovy form. About 22% of HD patients in STEP UP reported skin-sensation changes — burning, tingling, or feelings of electrical shock — versus 6% at 2.4 mg and 0.3% on placebo. The FDA explicitly noted these reactions occurred more often at the higher dose and said it “is currently conducting further investigations regarding this drug reaction.”

Here's the pivot that matters: Wegovy HD does NOT have the gentlest side-effect profile — if side-effect sensitivity is your top concern, the 2.4 mg injection or the Wegovy pill is the better call. But because HD is specifically designed for people already tolerating 2.4 mg who've hit a plateau, most HD candidates have already demonstrated they can handle semaglutide at a meaningful dose. If that's you, the dysesthesia signal is a known, usually resolvable tradeoff for a higher weight-loss ceiling — not a dealbreaker.

Most reported cases of dysesthesia resolved on their own, or with dose reduction back to 2.4 mg. If you start HD and get these symptoms, call your prescriber — don't tough it out, and don't stop on your own without telling them.

Side effects a priority for you? Start at the tablet path at SHED → or see the standard 2.4 mg pen at Sesame →.

Shared boxed warning (both products)

Semaglutide caused thyroid C-cell tumors in rodent studies. Whether it does the same in humans is unknown. Do not take either form of Wegovy if you or a family member has medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other warnings and precautions to discuss with your prescriber

• Pancreatitis (inflammation of the pancreas) — warning/precaution, not an absolute exclusion
• Gallbladder disease and gallstones
• Acute kidney injury
• Hypoglycemia when combined with insulin or sulfonylureas
• Diabetic retinopathy (in people with type 2 diabetes)
• Increased heart rate
• Pregnancy: stop Wegovy at least 2 months before a planned pregnancy; do not breastfeed while on the tablet

Note: The prior warning about suicidal behavior and ideation was removed from the current Wegovy prescribing information in January 2026. The FDA's preliminary April 2026 review did not find evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. This list is not exhaustive — read the full prescribing information and talk to a licensed clinician before starting.

Can You Switch Between Wegovy Formats?

The quick answer: Yes, with one honest caveat. The current Wegovy prescribing information gives explicit switching guidance between the 2.4 mg injection and the 25 mg tablets. It does not spell out a specific HD-to-tablet or tablet-to-HD protocol — so we'll tell you exactly what the label says and flag what it doesn't.

What the label explicitly covers

Wegovy 2.4 mg injection → Wegovy 25 mg tablets: “One week after discontinuing Wegovy 2.4 mg injection, initiate 25 mg tablets once daily.”

Wegovy 25 mg tablets → Wegovy 2.4 mg injection: “The day after discontinuing Wegovy 25 mg tablets, initiate Wegovy 2.4 mg injection once weekly.” The label adds that for patients who do not tolerate the 25 mg tablet, prescribers may consider switching to the 1.7 mg injection instead.

Crucial rule (in the label): Do not combine Wegovy injection with Wegovy tablets. Do not take Wegovy alongside Ozempic, Rybelsus, or any other GLP-1 receptor agonist. They all work on the same receptor — stacking them is dangerous.

What the label doesn't explicitly cover

The current prescribing information does not lay out a specific HD 7.2 mg ↔ 25 mg tablet switch protocol. Moving between HD and tablets is a prescriber conversation using the 2.4 mg ↔ tablet guidance as the reference point, not a step-by-step rule in the label. If Novo updates the prescribing information with explicit HD switching guidance, we'll update this section. Until then, we're not going to fabricate a protocol we can't source.

What this means for you practically

• On 2.4 mg, want to try the pill: clearly documented, straightforward switch — ask your prescriber.
• On the pill, want to move to 2.4 mg: also clearly documented.
• On 2.4 mg, want to try HD: stay on 2.4 mg for at least 4 weeks, then titrate up under your prescriber's guidance.
• On the pill, want HD: usually means switching to 2.4 mg first, tolerating for 4 weeks, then stepping up. Your prescriber will map the exact path.
• On HD, want to try the pill: not spelled out in the current label. Prescriber call.

Don't improvise GLP-1 switches. Don't stack them. Don't skip titration. Side effects are manageable when you titrate — they get rough fast when you don't.

Where to Actually Get Wegovy HD or the Wegovy Pill in 2026

The quick answer: As of April 2026, a handful of telehealth providers offer authentic, FDA-approved Wegovy online — but they differ sharply on which formats are explicitly listed, membership fees, insurance handling, and pricing transparency. Our access matrix below was verified against live provider pages. We flag what's confirmed and what still needs verification before you click.

The RX Index Access Matrix

Our featured paths

For the Wegovy pill (new starters, needle-averse, budget-first):

SHED is our first pick for the pill-focused reader. It explicitly lists Wegovy pill access at $149/month starting dose and converts well for people who know they want the tablet route. Spot-check the membership fee at checkout before committing — we've seen both $99 and $125 show up in different parts of the site.

See Wegovy pill availability and pricing at SHED →

Sesame Care is our second pick — slightly lower entry membership ($59/month on the annual Success by Sesame plan), same $149 starter-dose price on the pill, and a same-day provider visit if you want a clinician conversation before committing.

See Wegovy pill options through Sesame →

For Wegovy HD (already on 2.4 mg, need the step-up):

Hims & Hers is currently the only mainstream telehealth provider we've verified that explicitly shows both Wegovy pill access and Wegovy pen access up to 7.2 mg on-page. That makes it the cleanest path for the plateaued-on-2.4-mg reader who's already had the prescriber conversation and is ready to step up.

Check Wegovy HD eligibility through Hims →

For insurance-first readers (either format):

Ro is the strongest path if you need insurance navigation, prior-authorization support, or a recognizable name-brand telehealth feel. Get started for $39, then as low as $74/month with annual plan paid upfront. Ro was also one of the original launch partners for Novo Nordisk's multi-month subscription program on March 31, 2026.

See if Ro can get Wegovy covered for you →

For readers who want flexibility (branded plus compounded alternatives):

Eden offers both FDA-approved branded Wegovy and compounded semaglutide options. The tradeoff: Eden's branded Wegovy price is significantly higher than the Novo-authenticated telehealth subscription partners. If your goal is the lowest legitimate price on FDA-approved Wegovy, a Novo subscription partner is the better call.

See Eden’s weight-loss programs →

FAQ — The Questions That Would Send You Back to Search

Is Wegovy HD stronger than the Wegovy pill?

Wegovy HD produces more weight loss on average in its pivotal trial (~18.7% at 72 weeks, up to ~20.7% with full adherence) than the Wegovy pill (~13.6% at 64 weeks, up to ~16.6% with full adherence). But these weren't head-to-head studies — they had different patient populations and durations. HD also has a higher rate of side effects, notably dysesthesia at the 7.2 mg dose.

Can you start Wegovy HD without taking regular Wegovy first?

No. The FDA label only allows HD after you've tolerated Wegovy 2.4 mg for at least 4 weeks and your prescriber has determined additional weight reduction is clinically indicated. It's a step-up dose, not a starter.

What dose does a new Wegovy patient actually start at?

On the tablet path: 1.5 mg daily for the first 30 days, titrating to 4 mg, 9 mg, and finally 25 mg maintenance around day 91. On the injection path: 0.25 mg weekly for 4 weeks, titrating to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg maintenance around week 17. HD 7.2 mg is only available after at least 4 more weeks of tolerating 2.4 mg, if clinically indicated.

How much weight do you lose on Wegovy HD vs the pill?

In clinical trials: Wegovy HD, about 18.7% of body weight on average (~47 lb from a baseline of ~248 lb); Wegovy pill, about 13.6% on average (~33 lb from a baseline of ~235 lb). Idealized numbers (if everyone stayed fully on treatment): about 20.7% for HD and 16.6% for the pill.

Is the Wegovy pill as effective as the injection?

Compared to the standard 2.4 mg injection, yes — they look roughly equivalent on weight loss. Compared to the higher-dose 7.2 mg HD injection, no — HD has a meaningfully higher weight-loss ceiling in its trial.

What's the difference between Wegovy HD and regular Wegovy?

“Regular Wegovy” usually refers to the 2.4 mg once-weekly maintenance injection. Wegovy HD is a higher 7.2 mg once-weekly injection, approved only for adults who've tolerated 2.4 mg for at least 4 weeks and still need more weight loss. Both contain semaglutide; HD is the step-up option.

Does Wegovy HD cost more than the Wegovy pill?

Yes. Novo's current self-pay prices: $399/month for HD vs $299/month for the 25 mg pill at maintenance, and as low as $149/month for the pill's starter doses. The pill is also in Novo's multi-month subscription program at $249/month on the 12-month plan; HD was not included at launch and is expected to be added later.

How do you switch from Wegovy pill to the injection, or from the injection to the pill?

The current Wegovy prescribing information says: one week after your last 2.4 mg injection, start 25 mg tablets once daily; or, the day after your last 25 mg tablet, start 2.4 mg injection once weekly. For patients who don't tolerate the 25 mg tablet, prescribers may consider switching to the 1.7 mg injection. The label does not explicitly cover an HD 7.2 mg ↔ 25 mg tablet protocol.

Can you switch from Wegovy pill to Wegovy HD directly?

Not directly under the current label. The standard path would be: pill → 2.4 mg injection → tolerate for 4 weeks → HD. Don't improvise a shortcut — talk to your prescriber.

Does either version lower heart attack or stroke risk?

Wegovy 1.7 mg and 2.4 mg injection and Wegovy 25 mg tablets are FDA-approved to reduce the risk of major cardiovascular events in adults with known heart disease plus obesity or overweight, based on the SELECT trial of 17,604 participants. Wegovy HD 7.2 mg is approved as a step-up dose for weight reduction — it appears in the weight-reduction dosing section of the label, not the cardiovascular-risk-reduction section.

Is Wegovy HD included in Novo's subscription pricing yet?

No, not at the March 31, 2026 launch. Novo's press release stated HD 7.2 mg “will be added at a later date.” Until then, HD stays at the $399/month savings-offer price.

How do you travel with Wegovy HD vs the Wegovy pill?

Wegovy pens (including HD) need refrigeration but can stay at room temperature up to 28 days between 46°F and 86°F, protected from direct sunlight. The Wegovy pill is stored at room temperature in its original bottle — no refrigeration, easier for travel. Both are brand-name prescription medications, so bring a copy of your prescription for international trips.

Is the Wegovy pill the same as Rybelsus?

No. Both are oral semaglutide tablets from Novo Nordisk, but they're different products with different indications. Rybelsus is FDA-approved for type 2 diabetes and comes in 3 mg, 7 mg, and 14 mg strengths. The Wegovy pill is FDA-approved for weight management and cardiovascular event reduction at 25 mg. Different label, different dose range, different approved use.

Do I have to take the Wegovy pill on an empty stomach?

Yes, and the rules are strict. Take it first thing in the morning on an empty stomach with no more than 4 oz of plain water. Wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other medications. Missing the timing reduces absorption — less than 1% of the dose reaches the bloodstream even under ideal conditions.

Is Wegovy HD or the Wegovy pill covered by Medicare or Medicaid?

Traditional Medicare doesn't cover either for weight management, though the cardiovascular-event-reduction indication has been a pathway for some beneficiaries. The Medicare GLP-1 Bridge program was announced to launch July 2026 with a $50/month copay for eligible Part D beneficiaries — verify enrollment rules when live. State Medicaid coverage varies; California's Medi-Cal stopped covering Wegovy for weight management January 1, 2026.

What We Actually Verified

We treat this box like a product feature, not a disclaimer. If a claim on this page isn't traceable to one of the sources below, it shouldn't be on the page.

Sources reviewed:

• Current Wegovy FDA prescribing information (215256s029lbl.pdf, January 2026 revision)
• FDA press release: approval of Wegovy HD 7.2 mg (March 19, 2026)
• FDA press release: Wegovy pill approval (December 22, 2025)
• Novo Nordisk press release: Wegovy pill approval and OASIS 4 topline, December 22, 2025
• Novo Nordisk press release: Wegovy HD approval and STEP UP topline, March 19, 2026
• Novo Nordisk press release: multi-month subscription program launch, March 31, 2026
• Novo Nordisk announcement (February 2026): 2027 list price reduction to $675/month for Wegovy 2.4 mg injection and Wegovy 25 mg tablets
• NovoCare Pharmacy self-pay pricing guide, April 2026
• STEP UP trial results, The Lancet Diabetes & Endocrinology, November 2025
• OASIS 4 trial results, The New England Journal of Medicine, 2025
• SELECT trial results and the FDA cardiovascular indication
• FDA April 2026 preliminary review: no evidence GLP-1 RA use causes suicidal thoughts or actions
• California Medi-Cal January 2026 coverage change documentation
• Live provider pages spot-checked: SHED, Sesame Care, Hims & Hers, Ro, Eden, GoodRx

Items flagged [NEEDS VERIFICATION]:

• SHED membership fee display inconsistency ($99 vs $125 depending on section of site)
• Explicit HD listing on Ro and Sesame product pages
• HD-specific switch protocol language in the current FDA prescribing information
• Any HD-specific 2027 list-price change (February 2026 Novo announcement covered the 2.4 mg injection and 25 mg tablets only)

Last verified: April 17, 2026 · Next scheduled verification: May 17, 2026 · Refresh triggers: Novo pricing announcements, FDA label updates, provider pricing changes, subscription program updates, state Medicaid changes, Medicare GLP-1 Bridge program launch (July 2026), any HD-specific list price announcement.

Final Call: Where to Go From Here

You now know more about the Wegovy HD vs Wegovy pill decision than 95% of the internet. Here's where to actually go based on where you landed: